The relevance of heart failure severity for treatment with evidence‐based pharmacotherapy in general practice
- 24 March 2003
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 5 (2) , 187-193
- https://doi.org/10.1016/s1388-9842(02)00202-7
Abstract
AIMS: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is sub-optimal. Traditionally, assessment of drug use in heart failure has focused on the use of individual agents irrespective of CHF severity. This study investigates drug use for CHF patients in general practice with respect to the available evidence, incorporating both disease severity and the use of combination drug regimes. METHODS AND RESULTS: A cross-sectional survey of 769 Dutch CHF patients was performed as part of IMPROVEMENT of HF study. For each New York Heart Association severity classification the minimum treatment appropriate for the heart failure severity according to the scientific evidence available at the time of the study (1999) was defined. The proportion of patients treated with each drug increased with increasing severity, with the exception of the beta-blockers. Patients with less severe heart failure were approximately four to eight times more likely to receive evidence-based treatment than those with more severe heart failure. DISCUSSION: To assess pharmacological treatment of heart failure, in relation to the available evidence, it is important to take severity into account. While the number of drugs prescribed increased with increasing severity, the use of evidence-based regimes was lower in patients with more severe heart failure.7 page(sKeywords
This publication has 20 references indexed in Scilit:
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure: The replacement of angiotensin converting enzyme inhibition (REPLACE) investigatorsInternational Journal of Cardiology, 2001
- Modern management of hypertension and heart failure: evidence and practiceHeart, 2000
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000
- Differences in drug treatment of chronic heart failure between European countriesEuropean Heart Journal, 1999
- Differences Between Primary Care Physicians and Cardiologists in Management of Congestive Heart Failure: Relation to Practice GuidelinesJournal of the American College of Cardiology, 1997
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987